## JKHY: Jack Henry & Associates, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_20 2.0% below STRENGTH zone (4.0-10.0%); PEG 3.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($177.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Wells Fargo Reaffirms Their Hold Rating on Jack Henry & Associates (JKHY)**
- Source: The Globe and Mail | 20251221T050800 | Neutral | Relevance: 100%
- Wells Fargo analyst Jason Kupferberg has reiterated a Hold rating on Jack Henry & Associates (JKHY) with a $174.00 price target. This comes despite the company reporting increased revenue and net profit for its latest quarter, and while other firms like William Blair have maintained a Buy rating. Corporate insider sentiment for JKHY is negative, with recent insider stock sales.

**2. Riverbridge Partners LLC Has $16.37 Million Stake in Jack Henry & Associates, Inc. $JKHY**
- Source: MarketBeat | 20251222T124035 | Somewhat-Bullish | Relevance: 100%
- Riverbridge Partners LLC reduced its stake in Jack Henry & Associates (NASDAQ:JKHY) by 7.1% during the third quarter, now holding 109,904 shares valued at $16.37 million. Jack Henry & Associates exceeded Q3 earnings expectations with EPS of $1.97 and revenue of $636.11 million, setting FY 2026 guidance at 6.38-6.49 EPS. The company holds a "Moderate Buy" consensus rating from analysts with a $190.44 price target, though insiders have recently sold shares.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | RBC Capital | $210 | $185 | +14% |
| 2025-12-15 | Baird | $200 | $180 | +11% |
| 2025-12-08 | Keefe, Bruyette | $215 | $170 | +26% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | RBC Capital | up | Outperform |
| 2025-12-15 | Baird | main | Neutral |
| 2025-12-08 | Keefe, Bruyette | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.00M) |
| Sells | 4 ($3.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.9%)
- Blackrock Inc.: 8.4% (-2.0%)
- Kayne Anderson Rudni: 6.3% (-2.7%)
- State Street Corpora: 5.7% (+2.4%)
- Morgan Stanley: 3.5% (-52.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Valuation stretched: PEG 3.0x requires aggressive growth execution.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.02 signals overvaluation risk, limited margin of safety. Forward P/E 27.2x stretched relative to 9% growth. Quality metrics strong (ROE 23%, ROA 13%, margin 20%). Balance sheet: low leverage (D/E 0.40). Analyst sentiment positive (3 raises, avg +17%). Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.5B |
| Beta | 0.73 |
| 52W Range | $144.12 - $196.00 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.02 |
| Forward P/E | 27.2 |
| Current P/E | 29.5 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.9% to 2.0% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.00% (CS: 67) | Neutral |
| RSI_14 | 68.7 | Neutral |
| MACD Histogram | -0.41 | Bearish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $185.33
- **Stop Loss:** $177.91 (4.0% risk)
- **Target:** $192.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 161
- **Position Value:** $29,838.13
- **Portfolio %:** 29.84%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $1.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.65 | $1.86 | +12.8% |
| 2025Q2 | $1.50 | $1.56 | +4.1% |
| 2025Q1 | $1.33 | $1.45 | +8.7% |
| 2024Q4 | $1.32 | $1.35 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*